-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180

Benzinga·04/06/2026 15:13:11
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $200 to $180.